Ceftibuten

From Wikipedia, the free encyclopedia
  (Redirected from Cedax)
Jump to navigation Jump to search
Ceftibuten
Ceftibuten-Formulae.png
Clinical data
Trade namesCedax
AHFS/Drugs.comMonograph
MedlinePlusa698023
ATC code
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.238.211 Edit this at Wikidata
Chemical and physical data
FormulaC15H14N4O6S2
Molar mass410.42 g·mol−1
3D model (JSmol)
  (verify)

Ceftibuten is a third-generation cephalosporin antibiotic. It is an orally administered agent, with two dosage forms, capsule or oral suspension. It is marketed by Pernix Therapeutics under the trade name Cedax.

Medical uses[edit]

Ceftibuten is used to treat acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis. It is also indicated for pneumonia, infections of the urinary tract, enteritis, and gastroenteritis.[citation needed]

Adverse effects[edit]

In 3,000 patients, ceftibuten was well tolerated. The most frequent reactions were gastrointestinal and nausea.

Spectrum of susceptibility[edit]

Ceftibuten is active against Haemophilus influenzae, Moraxella catarrhalis, Escherichia coli, Klebsiella pneumoniae, K. oxytoca, Proteus vulgaris, P. mirabilis, P. providence, Salmonella sp., Shigella sp., Enterobacter sp., and Streptococcus sp.

The following represents minimum inhibitory concentration (MIC) susceptibility data for a few clinically significant microorganisms:

  • Haemophilus influenzae: 0.015–1.0 μg/ml
  • Moraxella catarrhalis: 0.5–4.0  μg/ml
  • Streptococcus pneumoniae: 0.5–256 μg/ml [1]

References[edit]

External links[edit]